Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/22/2026

1. DHR
2. USO
3. NVDA
4. SPY
5. SMCI
6. NOW
7. AMD
8. GM
9. EFX
10. IBM

Go back to Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody
SmartPros Ltd. (NASDAQ: SPRO) Delayed: 1.27 -0.11 (7.97%)
Previous Close $1.38    52 Week High $3.85 
Open $1.38    52 Week Low $1.25 
Day High $1.41    P/E N/A 
Day Low $1.25    EPS $-0.28 
Volume 1,990,403